Evommune, Inc.

Healthcare · Biotechnology · United States

Last price 6.73 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 244.25M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.